VACUNAS COVID

Bibliografía

  • Gobierno de México. Secretaría de Salud. COFEPRIS. Autorización para uso de emergencia a vacuna astrazeneca covid-19. 4-Ene-2021. Revisado el 8 de Febrero de 2021 de la página: https://www.gob.mx/cofepris/articulos/autorizacion-para-uso-de-emergencia-a-vacuna-astrazeneca-covid-19?idiom=es
  • Gobierno de México. Secretaría de Salud. COFEPRIS. 046. Otorga Cofepris autorización para uso de emergencia de vacuna Sputnik V. 2-Feb-2021. Revisado el 8 de Febrero de 2021 de la página: https://www.gob.mx/salud/prensa/046-otorga-cofepris-autorizacion-para-uso-de-emergencia-de-vacuna-sputnik-v
  • Gobierno de México. Secretaría de Salud. COFEPRIS. La cofepris otorga autorización para uso de emergencia a vacuna para prevenir la enfermedad por coronavirus (COVID 19). 11-Dic-2020. Revisado el 8 de Febrero de 2021 de la página: https://www.gob.mx/cofepris/articulos/la-cofepris-otorga-autorizacion-para-uso-de-emergencia-a-vacuna-para-prevenir-la-enfermedad-por-coronavirus-covid-19
  • Gobierno de México. Secretaría de Salud. COFEPRIS. 061. Cofepris autoriza vacuna fabricada por Sinovac para uso de emergencia contra COVID-19. 10-Feb-2021. Revisado el 26 de Marzo de 2021 de la página: https://www.gob.mx/salud/prensa/061-cofepris-autoriza-vacuna-fabricada-por-sinovac-para-uso-de-emergencia-contra-covid-19
  • Gobierno de México. Secretaría de Salud. COFEPRIS. COFEPRIS autoriza el uso de emergencia para lotes envasados en México de la vacuna CanSino. Revisado el 26 de Marzo de 2021 de la página: https://www.gob.mx/cofepris/articulos/cofepris-autoriza-el-uso-de-emergencia-para-lotes-envasados-en-mexico-de-vacuna-cansino?idiom=es
  • Sinovac Announces Phase III Results of Its COVID-19 Vaccine. Press releases 05-02-2021. Revisado el 11 de Febrero de 2021 de la página: http://www.sinovacbio.com/?optionid=754&auto_id=922
  • Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O’Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98. PMID: 33306989; PMCID: PMC7723445.
  • Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 2:S0140-6736(21)00234-8. doi: 10.1016/S0140-6736(21)00234-8. Epub ahead of print. PMID: 33545094; PMCID: PMC7852454.
  • Prognosis China’s CanSino Covid Vaccine Shows 65.7% Efficacy. 8-Feb-2021. Revisado el 11 de Febrero de 2021 de la página: https://www.bloomberg.com/news/articles/2021-02-08/pakistan-says-cansino-s-covid-vaccine-shows-65-7-efficacy
  • Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181.
  • Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 Feb 19:S0140-6736(21)00432-3. doi: 10.1016/S0140-6736(21)00432-3. Epub ahead of print. PMID: 33617777; PMCID: PMC7894131.
  • Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021 Feb 24. doi: 10.1056/NEJMoa2101765. Epub ahead of print. PMID: 33626250.
  • Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Kwatra G, Ahmed K, Aley P, Bhikha S, Bhiman JN, Bhorat AE, du Plessis J, Esmail A, Groenewald M, Horne E, Hwa SH, Jose A, Lambe T, Laubscher M, Malahleha M, Masenya M, Masilela M, McKenzie S, Molapo K, Moultrie A, Oelofse S, Patel F, Pillay S, Rhead S, Rodel H, Rossouw L, Taoushanis C, Tegally H, Thombrayil A, van Eck S, Wibmer CK, Durham NM, Kelly EJ, Villafana TL, Gilbert S, Pollard AJ, de Oliveira T, Moore PL, Sigal A, Izu A; NGS-SA Group Wits–VIDA COVID Group. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 Mar 16. doi: 10.1056/NEJMoa2102214. Epub ahead of print. PMID: 33725432.
  • Bharat Biotech. COVAXIN® – India’s First Indigenous COVID-19 Vaccine. Revisado el 31 de Mayo de 201 en: https://www.bharatbiotech.com/covaxin.html
  • Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF, Marovich MA, Neuzil KM, Corey L, Cauwenberghs N, Tanner T, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021 Apr 21. doi: 10.1056/NEJMoa2101544. Epub ahead of print. PMID: 33882225.
  • Secretaría de Salud. Guía técnica para la aplicación de la Vacuna Cansino contra el Virus SARS-CoV-2. Revisado el 28 de Junio de 2021 en: https://coronavirus.gob.mx/wp-content/uploads/2021/03/GTApp_Cansino_16Mar2021.pdf
  • Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, Swanson KA, Ma H, Xu X, Koury K, Kalina WV, Cooper D, Jennings T, Brandon DM, Thomas SJ, Türeci Ö, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021 May 27:NEJMoa2107456. doi: 10.1056/NEJMoa2107456. Epub ahead of print. PMID: 34043894; PMCID: PMC8174030.
  • CDC. Dosis de refuerzo de la vacuna contra el COVID-19. Revisado el 7 de Enero de 2022 en: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html
  • European medicines agency. EMA and ECDC recommendations on heterologous vaccination courses against COVID-19: ‘mix-and-match’ approach can be used for both initial courses and boosters. Revisado el 7 de Enero de 2022 en:  https://www.ema.europa.eu/en/news/ema-ecdc-recommendations-heterologous-vaccination-courses-against-covid-19-mix-match-approach-can-be
  • UK health security agency. Guidance. COVID-19 vaccination: a guide to booster vaccination for individuals aged 18 years and over and those aged 16 years and over who are at risk.  Revisado el 7 de Enero de 2022 en:  https://www.gov.uk/government/publications/covid-19-vaccination-booster-dose-resources/covid-19-vaccination-a-guide-to-booster-vaccination-for-individuals-aged-18-years-and-over
#QueLaVacunaNosUna
u

¿Cuando y donde me puedo vacunar?

Entra al siguiente link

Síguenos en nuestras redes sociales

Suscríbete a nuestro sitio

vacunacion.org | Desarrollado por Equilibrio Visual

¿DUDAS? PREGUNTALE A @DOC